Stocks of Edwards Lifesciences Corp (NYSE:EW) traded higher last session on Wall Street, down -1.70% to $61.71.
According to the data, Edwards Lifesciences Corp (NYSE:EW) has 32 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $105.00 and a low of $63.00, we find $81.00. Given the previous closing price of $62.78, this indicates a potential upside of 29.02 percent. EW stock price is now -15.00% away from the 50-day moving average and -23.83% away from the 200-day moving average. The market capitalization of the company currently stands at $37.51B.
A total of 13 analysts have issued a hold rating and 14 have given it a buy rating. Brokers who have rated the stock have averaged $82.23 as their price target over the next twelve months.
With the price target maintained at $90, Oppenheimer recently Upgraded its rating from Perform to Outperform for Edwards Lifesciences Corp (NYSE: EW).
In other news, Wood Larry L, Global President TAVR & Surg sold 8,660 shares of the company’s stock on Oct 13. The stock was sold for $606,198 at an average price of $70.00. Upon completion of the transaction, the Global President TAVR & Surg now directly owns 213,794 shares in the company, valued at $13.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 13, CVP,Strategy/Corp Development BOBO DONALD E JR sold 5,000 shares of the business’s stock. A total of $349,909 was realized by selling the stock at an average price of $69.98. This leaves the insider owning 39,503 shares of the company worth $2.44 million. Insiders disposed of 956,974 shares of company stock worth roughly $59.05 million over the past 1 year. A total of 1.56% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corp shares was purchased by STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD during the first quarter worth $74,762,000. BOWEN HANES & CO INC invested $21,916,000 in shares of EW during the first quarter. In the first quarter, ARDEVORA ASSET MANAGEMENT LLP acquired a new stake in Edwards Lifesciences Corp valued at approximately $16,256,000. ING GROEP NV acquired a new stake in EW for approximately $13,040,000. UNISUPER MANAGEMENT PTY LTD purchased a new stake in EW valued at around $12,357,000 in the second quarter. In total, there are 1,798 active investors with 85.46% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $63.10 for Edwards Lifesciences Corp (NYSE: EW). During the past 12 months, Edwards Lifesciences Corp has had a low of $61.50 and a high of $94.87. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.28, and a quick ratio of 2.45. According to the stock market information, the enterprise value for the company is $36.34B, which is based on a 26.39 price-to-earnings ratio, a 3.01 price-to-earnings-growth ratio, and a beta of 1.03. The fifty day moving average price for EW is $72.30 and a two-hundred day moving average price translates $80.93 for the stock.
The latest earnings results from Edwards Lifesciences Corp (NYSE: EW) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at $0.66, beating analysts’ expectations of $0.65 by 0.01. This compares to $0.65 EPS in the same period last year. The net profit margin was 24.59% and return on equity was 22.23% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.37 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.38 percent. For the current quarter, analysts expect EW to generate $1.48B in revenue.
Edwards Lifesciences Corp(EW) Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
